Stockscreener 앱 받기
58.85
5.11%
2.86
시장 영업 전:
58.48
-0.37
-0.63%
전일 마감가:
$55.99
열려 있는:
$55.99
하루 거래량:
2.56M
Relative Volume:
1.02
시가총액:
$5.61B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-21.02
EPS:
-2.8
순현금흐름:
$-191.20M
1주 성능:
+10.41%
1개월 성능:
+4.33%
6개월 성능:
+54.66%
1년 성능:
+15.08%
1일 변동 폭
$54.93
$59.77
1주일 범위
$51.00
$59.77
52주 변동 폭
$30.04
$78.48
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
CRSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
58.85 | 5.34B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-18 | 개시 | JP Morgan | Overweight |
| 2025-02-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-02-12 | 업그레이드 | TD Cowen | Sell → Hold |
| 2025-02-03 | 개시 | H.C. Wainwright | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown - MSN
Will CRISPR Therapeutics AG (1CG) stock return to pre crash levelsWeekly Trade Report & Weekly High Potential Stock Alerts - Newser
Is CRISPR Therapeutics AG stock a bargain at current levelsJuly 2025 Catalysts & Safe Capital Investment Plans - Newser
Cathie Wood’s Buys And Rumors Aside, Here’s Why Crispr Therapeutics Is A Strong Buy (CRSP) - Seeking Alpha
Rhumbline Advisers Buys New Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Nasdaq Index Biotech Momentum - Kalkine Media
Bernstein Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Will CRISPR Therapeutics AG stock continue upward momentumLayoff News & Weekly Top Stock Performers List - Newser
Can CRISPR Therapeutics AG (1CG) stock deliver double digit returnsMarket Volume Summary & Long Hold Capital Preservation Tips - Newser
How dovish Fed policy supports CRISPR Therapeutics AG (1CG) stockJuly 2025 EndofMonth & Fast Entry High Yield Stock Tips - Newser
Will CRISPR Therapeutics AG (1CG) stock outperform benchmarksMarket Sentiment Summary & High Conviction Buy Zone Picks - Newser
Will CRISPR Therapeutics AG (1CG) stock outperform value peers2025 Price Targets & High Accuracy Trade Alerts - Newser
Will CRISPR Therapeutics AG (1CG) stock hit analyst forecastsMarket Sentiment Summary & AI Based Trade Execution Alerts - Newser
CRISPR Therapeutics: CTX310 De-Risks, CASGEVY Disappoints Amid Takeover Rumors (CRSP) - Seeking Alpha
The Best CRISPR Companies for 2025 - The Motley Fool
Crispr Therapeutics (CRSP) Gains Amid Takeover Speculation - GuruFocus
Crispr Therapeutics pares loss amid takeover speculation (CRSP:NASDAQ) - Seeking Alpha
Inflation Data: Can SGBX stock maintain operating marginsMarket Performance Recap & Detailed Earnings Play Alerts - BỘ NỘI VỤ
Crispr Therapeutics (CRSP) Shares React to M&A Rumor - GuruFocus
Crispr Therapeutics rumor highlighted in Betaville blog - TipRanks
Loomis Sayles & Co. L P Has $41.68 Million Stock Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
What CRISPR Therapeutics’ (CRSP) Latest Trial Results Mean for Investors - MSN
West Family Investments Inc. Takes Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG $CRSP Shares Sold by Cetera Investment Advisers - MarketBeat
Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50% - The Motley Fool
Ameritas Investment Partners Inc. Purchases Shares of 8,451 CRISPR Therapeutics AG $CRSP - MarketBeat
Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy - Insider Monkey
CRISPR Therapeutics (CRSP): Assessing Valuation in Light of Recent Share Price Volatility - Yahoo Finance
Why CRISPR Therapeutics AG (1CG) stock could be next leaderWeekly Investment Summary & Technical Buy Zone Confirmation - BỘ NỘI VỤ
Why CRISPR Therapeutics (CRSP) Is Up 6.1% After Positive CTX310 Trial and Earnings Beat - Sahm
Price-Driven Insight from (CRSP) for Rule-Based Strategy - news.stocktradersdaily.com
CRISPR Therapeutics (CRSP): Exploring Valuation After Analyst Upgrades and Q3 Clinical Progress - Sahm
Himension Capital Singapore PTE. LTD. Sells 10,454 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Magnetar Financial LLC Invests $319,000 in CRISPR Therapeutics AG $CRSP - MarketBeat
Analysts Offer Insights on Healthcare Companies: ProMIS Neurosciences (PMN) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Chardan Capital Lowers Price Target for CRSP Despite Buy Rating - GuruFocus
Chardan Cuts Price Target on CRISPR Therapeutics to $74 From $82, Keeps Buy Rating - MarketScreener
Crispr Therapeutics price target lowered to $74 from $82 at Chardan - TipRanks
Aug PreEarnings: Is CRISPR Therapeutics AG stock positioned for long term growthJuly 2025 Pullbacks & Real-Time Market Sentiment Reports - BỘ NỘI VỤ
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform - MSN
Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance - MSN
Police & Firemen s Retirement System of New Jersey Makes New $911,000 Investment in CRISPR Therapeutics AG $CRSP - MarketBeat
Entropy Technologies LP Invests $1.06 Million in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics Hits Day High with 8.24% Surge in Stock Price - Markets Mojo
9 Oversold Biotech Stocks to Invest In - Insider Monkey
CRISPR Therapeutics Hits Day Low at $48.24 Amid Price Pressure - Markets Mojo
Does the Pullback Signal Opportunity for CRISPR Therapeutics After Gene Editing Approval? - Yahoo Finance
Intech Investment Management LLC Makes New $1.90 Million Investment in CRISPR Therapeutics AG $CRSP - MarketBeat
Del Sette Capital Management LLC Buys New Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
How the First CRISPR-Based Therapy Approval Impacts CRISPR Therapeutics’ Valuation - Sahm
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
1.10%
자본화:
|
볼륨(24시간):